A peptide binding to the tetraspanin CD9 reduces cancer metastasis
Issued Date
2023-03-01
Resource Type
eISSN
27729508
Scopus ID
2-s2.0-85146146961
Journal Title
Biomaterials Advances
Volume
146
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biomaterials Advances Vol.146 (2023)
Suggested Citation
Suwatthanarak T., Ito K., Tanaka M., Sugiura K., Hoshino A., Miyamoto Y., Miyado K., Okochi M. A peptide binding to the tetraspanin CD9 reduces cancer metastasis. Biomaterials Advances Vol.146 (2023). doi:10.1016/j.bioadv.2023.213283 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81710
Title
A peptide binding to the tetraspanin CD9 reduces cancer metastasis
Other Contributor(s)
Abstract
As an organizer of multi-molecular membrane complexes, the tetraspanin CD9 has been implicated in a number of biological processes, including cancer metastasis, and is a candidate therapeutic target. Here, we evaluated the suppressive effects of an eight-mer CD9-binding peptide (CD9-BP) on cancer cell metastasis and its mechanisms of action. CD9-BP impaired CD9-related functions by adversely affecting the formation of tetraspanin webs—networks composed of CD9 and its partner proteins. The anti-cancer metastasis effect of CD9-BP was evidenced by the in vitro inhibition of cancer cell migration and invasion as well as exosome secretion and uptake, which are essential processes during metastasis. Finally, using a mouse model, we showed that CD9-BP reduced lung metastasis in vivo. These findings provide insight into the mechanism by which CD9-BP inhibits CD9-dependent functions and highlight its potential application as an alternative therapeutic nano-biomaterial for metastatic cancers.